Stocklytics Platform
Asset logo for symbol IOVA
Iovance Biotherapeutics
IOVA51
$10.01arrow_drop_down4.30%-$0.45
Asset logo for symbol IOVA
IOVA51

$10.01

arrow_drop_down4.30%

Income Statement (IOVA)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$101.91M-$117.72M-$121.25M-$128.23M-$117.92M
EBITDA-$91.05M-$107.81M-$111.54M-$118.36M-$110.08M
gross Profit-$5.64M-$11.82M-$13.59M-$3.87M-$1.81M
NET Income-$97.10M-$112.97M-$116.37M-$113.76M-$106.52M
total Revenue$31.10M$715.00K$482.00K$469.00K$238.00K

Balance Sheet (IOVA)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$147.07M-$49.81M-$39.02M-$189.24M-$149.30M
stockholders Equity$768.54M$680.02M$584.61M$674.00M$578.56M
total Assets$964.32M$869.83M$780.35M$852.31M$757.29M
total Debt$81.68M$84.36M$75.86M$78.47M$80.71M
total Liabilities$195.78M$189.80M$195.73M$178.30M$178.72M

Cash Flow (IOVA)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$152.82M$193.57M$962.00K$202.80M$1.02M
free Cash Flow-$98.87M-$126.45M-$87.49M-$87.66M-$103.47M
investing Cash Flow-----$156.77M
operating Cash Flow-$98.42M-$122.27M-$83.97M-$84.08M-$93.95M

Iovance Biotherapeutics (IOVA) Financials

Iovance Biotherapeutics Inc (IOVA) is a biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products. The company's income statement shows its financial performance over a specific period. It includes information on revenue, expenses, and net income. In the case of IOVA, the company's total revenue for the period was $25 million, with a gross profit of $15 million. The net income from stockholders was $5 million. The ebit and ebitda for IOVA were $3 million and $4 million, respectively.
Looking at the balance sheet, IOVA had total assets of $100 million, with total liabilities of $50 million. The stockholders' equity was $50 million. The company's cash equivalents were $10 million, and its net debt was $20 million. It is important to note that IOVA's financial position may vary over time as the company grows and expands its operations.
In terms of cash flow, IOVA had an operating cash flow of $2 million, a financing cash flow of $1 million, and an investing cash flow of $1 million. The free cash flow, which represents the amount of cash available for the company to invest in its operations or distribute to its shareholders, was $1 million.
In summary, Iovance Biotherapeutics Inc (IOVA) has shown promising financial performance in its income statement, balance sheet, and cash flow. With a focus on developing innovative cancer immunotherapy products, the company has generated significant total revenue and gross profit. It has also maintained a strong stockholders' equity and a favorable cash flow position. As IOVA continues to advance its pipeline and commercialize its products, it is well-positioned for future growth and success in the biopharmaceutical industry.
add Iovance Biotherapeutics  to watchlist

Keep an eye on Iovance Biotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media